Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03195452
Other study ID # RC16_0317
Secondary ID
Status Completed
Phase Phase 2
First received
Last updated
Start date November 8, 2017
Est. completion date May 6, 2020

Study information

Verified date May 2020
Source Nantes University Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Raltegravir (RAL) is a very effective antiretroviral drug with a favorable long term tolerability. RAL offers many advantages such as lack of drug-drug interactions, a good safety profile particularly on lipids, inflammation and bone parameters. Ral can be an very interesting for patient with comorbidities and comedications, intolerance or toxicities with their current ARV treatment. However its current formulation of one tablet of 400mg twice a day coul not suit many patients.

A new once-a-day formulation of RAL has been developed, with two tablets of 600 mg QD. Pharmacokinetic study in healthy volunteers has shown that this dosing provides increased RAL exposure compared to the standard formulation of 400 mg given twice a day.

The objective of this study is to evaluate the maintain of virologic suppression with raltegravir 600mg 2 tablets qd as part of a triple antiretroviral regimen in virologically controlled patients.


Recruitment information / eligibility

Status Completed
Enrollment 100
Est. completion date May 6, 2020
Est. primary completion date October 30, 2019
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Adults of both gender = 18 years

- Signed informed consent form

- Documented HIV-1 infection

- Stable antiretroviral therapy for = 6 months consisting of 2 NRTIs (TDF/FTC or ABC/3TC )+ a 3rd agent either as a once or twice daily regimen, unless there is intolerance requiring change of therapy. In this situation of intolerance, patient with less than 6 months of current antiretroviral therapy will be allowed in the study.

As soon as TAF/FTC will be available in France, patients receiving TAF/FTC + 3rd agent could be enrolled.

Switch of TDF/FTC to TAF/FTC will be authorized as long as the change has occurred for more than 3 months prior to the screening visit. Such switch will be also allowed during the study, and, unless urgently needed, after the W24 visit.

Patients on stable raltegravir 400 mg 1 tablet twice daily plus 2 NRTI can be enrolled; number of these patients will be limited to 33% of the total cohort.

- Indication to current change antiretroviral therapy for at least one of the following reasons :

1. Intolerance or prevention of toxicity

2. Presence of a comorbid condition justifying change of the 3rd agent

3. Management of drug-drug-interaction

4. Patient's request, including switch to simplify or to improve convenience

- No prior virological failure on integrase-containing antiretroviral therapy or NNRTI-containing antiretroviral therapy or NRTI only-therapy

- HIV-1 RNA < 50 c/mL for = 6 months. However, a single HIV-1 RNA = 50 copies/mL and < 200 copies/mL with a subsequent HIV-1 RNA < 50 c/mL in the past 6 months is allowed.

- AST and ALT < 5 times the upper limit of normal

- Estimated glomerular filtration rate by MDRD equation >= 50 mL/min

- Hemoglobin > 8 g/dL

- Platelet count > 50 0000/mm3

- For women of childbearing potential: negative serum test for pregnancy and acceptance to use contraceptive methods

- Affiliation to a French Social Security program.

Exclusion Criteria:

- HIV-2 co-infection

- Concomitant treatments contra-indicated with raltegravir

- Patients receiving raltegravir 400mg, 2 tablets in one daily intake

- Patients with prior virological failure on NRTI+PI/r based regimen can be enrolled as long as historical plasma genotype and/or screening DNA genotype demonstrate absence of resistance or possible resistance to any drug. Subjects with previous failure to any other antiretroviral regimen cannot be enrolled.

- Presence of possible resistance or resistance to any nucleoside reverse transcriptase inhibitor or integrase inhibitor on a historical plasma genotype.

- Presence of possible resistance or resistance to any non- nucleoside reverse transcriptase inhibitor on a historical plasma genotype, with the exception of polymorphic mutations E138A/G/K/Q/R/S and V179D in patients naïve to NNRTI.

- Presence of resistance to any PI on a historical plasma genotype

In case were historical plasma genotype being not available or incomplete, resistance genotype will be performed on DNA at screening visit. Full treatment and cumulative resistance genotype history will have to be provided, at screening, to the principal investigator to approve any inclusion.

- For HCV co-infected patients, if specific treatment for hepatitis is required during the trial duration, such HCV therapy should be compatible with the ARV combination and only started after the W24 visit.

- HBV infection, in the absence of treatment with TDF or TAF

- Severe associated diseases requiring specific treatment, such as curative treatment of acute opportunistic infection

- Treatment with interferon, interleukin or any immunotherapeutic agent or chemotherapy

- Cancer diagnosis in the past 3 years with the exception of Kaposi sarcoma

- Subjects participating in another clinical trial evaluating therapies and having an exclusion period that is still ongoing during the screening phase

- Any condition which might compromise the safety of treatment and/or patient's adherence to trial procedures

- Person under guardianship, trusteeship or deprived of freedom by a judicial or administrative decision

- Difficulty in terms of follow-up (vacation, job transfer, geographical distance, lack of motivation)

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Raltegravir and 2 Nucleoside/Nucleotide reverse transcriptase inhibitor (NRTI)
All virologically suppressed

Locations

Country Name City State
France CHU De Bordeaux Bordeaux
France CH de la Roche Sur Yon la Roche Sur Yon
France CH du Mans Le Mans
France CHU de Lyon Lyon
France CHRU de Montpellier Montpellier
France CHU of NANTES Nantes
France CHU de Nice Nice
France CHR orléans Orléans
France CHU de Bichat Paris
France CHu hotel dieu Paris
France CHU la pitié Paris
France Hopital Avicenne Paris
France Hopital Necker Paris
France Hopital St Louis Paris
France CHU de Reims Reims
France CH de Tourcoing Tourcoing
France CHRU de Tours Tours

Sponsors (1)

Lead Sponsor Collaborator
Nantes University Hospital

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of copie/ml plasma HIV - RNA 48 weeks
Secondary Score evaluation of patient satisfaction 48 weeks
Secondary Score evaluation of patient quality of life with PROQOL-HIV questionnaires 48 weeks
Secondary Score evaluation of adherence 48 weeks
Secondary Number of incidence of Treatment-Emergent Adverse Events 48 weeks
Secondary Number of patient who have a viral load < 50 copies/ml 48 weeks
Secondary number of discontinuation of Raltegravir 48 weeks
Secondary number of treatment failure 48 weeks
Secondary number of genotype resistance mutations 48 weeks
See also
  Status Clinical Trial Phase
Not yet recruiting NCT04575545 - Prevalence of COVID-19 Infection in a Cohort of Patients Infected by the HIV and Patients Taking PrEP
Active, not recruiting NCT04581746 - Impact of the Epidemic of COVID-19 Infection Among People Living With HIV (SARS-CoV-2) N/A
Not yet recruiting NCT05322083 - HIV A6 Genome In ART Unsuccessful Patients On DOR
Completed NCT05083273 - Life Experience of People Aged 60 and Over Living With HIV
Completed NCT04772469 - Self-Test Strategies and Linkage Incentives to Improve ART and PrEP Uptake in Men N/A
Terminated NCT02898896 - Coronary Artery Disease (CAD) in Suppressed HIV-infected N/A
Completed NCT03671291 - Missed Opportunities to Pre-exposure Prophylaxis for HIV Infection on Person Newly Diagnosed With HIV N/A